Fig. 1: Study overview detailing cohorts used for analyses within ERpHER2n and ERpHER2p disease. | Nature Communications

Fig. 1: Study overview detailing cohorts used for analyses within ERpHER2n and ERpHER2p disease.

From: Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer

Fig. 1: Study overview detailing cohorts used for analyses within ERpHER2n and ERpHER2p disease.The alternative text for this image may have been generated using AI.

. A Analyses comparing ERpHER2n-HER2E to the PAM50 subtypes LumA and LumB within ERpHER2n disease. B Analyses comparing ERpHER2n-HER2E to ERpHER2p disease subtyped as PAM50 HER2E or another subtype. ACT adjuvant chemotherapy, TME tumor microenvironment, DEG Differentially expressed gene, CNA Copy number alteration.

Back to article page